HRP20171611T1 - N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena - Google Patents
N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena Download PDFInfo
- Publication number
- HRP20171611T1 HRP20171611T1 HRP20171611TT HRP20171611T HRP20171611T1 HR P20171611 T1 HRP20171611 T1 HR P20171611T1 HR P20171611T T HRP20171611T T HR P20171611TT HR P20171611 T HRP20171611 T HR P20171611T HR P20171611 T1 HRP20171611 T1 HR P20171611T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 150000008331 benzenesulfonamides Chemical class 0.000 title 1
- ZLVPOPZOUSJLFL-UHFFFAOYSA-N n-(4-hydroxy-4-methylcyclohexyl)-4-phenylbenzenesulfonamide Chemical class C1CC(C)(O)CCC1NS(=O)(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 ZLVPOPZOUSJLFL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 78
- 150000003839 salts Chemical class 0.000 claims 33
- 239000012453 solvate Substances 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 206010065687 Bone loss Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000027496 Behcet disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000010029 ameloblastoma Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000000270 basal cell Anatomy 0.000 claims 2
- 208000016738 bone Paget disease Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000002997 osteoclast Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Claims (43)
1. Spoj, naznačen time, da je odabran od spojeva sa sljedećim formulama, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
2. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
3. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom,
ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
4. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
5. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
6. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
7. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
8. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
9. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
10. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
11. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
12. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju koji je odabran od spojeva sa sljedećim formulama, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
13. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
14. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
15. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
16. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
17. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
18. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
19. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
20. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
21. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
22. Spoj prema zahtjevu 12, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
23. Spoj prema zahtjevu 1, naznačen time, da se radi o spoju koji je odabran od spojeva sa sljedećim formulama, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
24. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
25. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
26. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
27. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
28. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
29. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
30. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
31. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
32. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
33. Spoj prema zahtjevu 23, naznačen time, da se radi o spoju sa sljedećom formulom, ili njegova farmaceutski prihvatljiva sol, njegov hidrat ili solvat:
[image]
34. Sastav, naznačen time, da obuhvaća spoj u skladu s bilo kojim od zahtjeva 1 do 33, i farmaceutski prihvatljiv nosač ili razrjeđivač.
35. Postupak proizvodnje sastava, naznačen time, da obuhvaća korak miješanja spoja u skladu s bilo kojim od zahtjeva 1 do 33, s farmaceutski prihvatljivim nosačem ili razrjeđivačem.
36. Spoj u skladu s bilo kojim od zahtjeva 1 do 33, naznačen time, da se upotrebljava u liječenju ljudskog ili životinjskog tijela putem terapeutske obrade.
37. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
reumatoidni artritis; psorijaza; psorijatički artritis; kronična opstrukcijska plućna bolest (COPD); astma; ateroskleroza; upalna bolest crijeva; ankilozni spondilitis;
multipla skleroza; sistemski eritematozni lupus; Sjogrenov sindrom;
poremećaj povezan s gubitkom kostiju, kao što je gubitak kostiju uslijed prekomjerne aktivnosti osteoklasta kod reumatoidnog artritisa, osteoporoze, bolesti kostiju povezane s rakom, ili Pagetove bolesti;
rak, kada se radi o hematološkoj malignosti, kao što je višestruki mijelom, leukemija, ili limfom, ili o raku čvrstih tumora, kao što je rak mjehura, rak dojke (ženski i/ili muški), rak debelog crijeva, karcinom renalnih stanica, rak bubrega, rak pluća, rak gušterače, rak želudca, rak prostate, rak mozga, rak kože, rak štitnjače, ameloblastom bazalnih stanica, ili melanom;
poremećaj povezan s fibrozom, kao što je sistemska skleroza ili skleroderma; ili
rijetki vaskulitis, kao što je Behçetova bolest.
38. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
reumatoidni artritis; psorijaza; psorijatički artritis; kronična opstrukcijska plućna bolest (COPD); astma; ateroskleroza; upalna bolest crijeva; ili ankilozni spondilitis.
39. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
multipla skleroza; sistemski eritematozni lupus; ili Sjogrenov sindrom.
40. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
poremećaj povezan s gubitkom kostiju, kao što je gubitak kostiju uslijed prekomjerne aktivnosti osteoklasta kod reumatoidnog artritisa, osteoporoze, bolesti kostiju povezane s rakom, ili Pagetove bolesti.
41. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
rak, kada se radi o hematološkoj malignosti, kao što je višestruki mijelom, leukemija, ili limfom, ili o raku čvrstih tumora, kao što je rak mjehura, rak dojke (ženski i/ili muški), rak debelog crijeva, karcinom renalnih stanica, rak bubrega, rak pluća, rak gušterače, rak želudca, rak prostate, rak mozga, rak kože, rak štitnjače, ameloblastom bazalnih stanica, ili melanom.
42. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
poremećaj povezan s fibrozom, kao što je sistemska skleroza ili skleroderma.
43. Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja:
rijetki vaskulitis, kao što je Behçetova bolest.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1311361.8A GB201311361D0 (en) | 2013-06-26 | 2013-06-26 | Compounds and their therapeutic use |
| EP14735642.2A EP3013799B1 (en) | 2013-06-26 | 2014-06-24 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
| PCT/GB2014/051921 WO2014207445A1 (en) | 2013-06-26 | 2014-06-24 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171611T1 true HRP20171611T1 (hr) | 2017-12-15 |
Family
ID=48998987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171611TT HRP20171611T1 (hr) | 2013-06-26 | 2017-10-24 | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US9624167B2 (hr) |
| EP (1) | EP3013799B1 (hr) |
| JP (1) | JP6360555B2 (hr) |
| KR (1) | KR102151299B1 (hr) |
| CN (1) | CN105492426B (hr) |
| AU (1) | AU2014300745B2 (hr) |
| BR (1) | BR112015031527B1 (hr) |
| CA (1) | CA2915075C (hr) |
| CY (1) | CY1119438T1 (hr) |
| DK (1) | DK3013799T3 (hr) |
| EA (1) | EA028077B1 (hr) |
| ES (1) | ES2641758T3 (hr) |
| GB (1) | GB201311361D0 (hr) |
| HK (1) | HK1218115A1 (hr) |
| HR (1) | HRP20171611T1 (hr) |
| HU (1) | HUE034983T2 (hr) |
| IL (1) | IL243103B (hr) |
| LT (1) | LT3013799T (hr) |
| ME (1) | ME02834B (hr) |
| MX (1) | MX2015016914A (hr) |
| NZ (1) | NZ715192A (hr) |
| PL (1) | PL3013799T3 (hr) |
| PT (1) | PT3013799T (hr) |
| RS (1) | RS56256B1 (hr) |
| SG (1) | SG11201510646SA (hr) |
| SI (1) | SI3013799T1 (hr) |
| WO (1) | WO2014207445A1 (hr) |
| ZA (1) | ZA201600202B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| GB201813312D0 (en) * | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| GB201905520D0 (en) * | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| KR19990067184A (ko) | 1995-10-30 | 1999-08-16 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 프로테아제 억제제 |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2421797A (en) | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| EP0939629A4 (en) | 1996-07-22 | 2002-07-17 | Monsanto Co | THIOL-SULFONAMIDES AS METALLOPROTEINAS INHIBITORS |
| IL129147A0 (en) | 1996-10-16 | 2000-02-17 | American Cyanamid Co | The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| ATE342262T1 (de) | 1996-11-27 | 2006-11-15 | Bristol Myers Squibb Pharma Co | Neue integrin rezeptor antagonisten |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| CA2289602A1 (en) | 1997-05-08 | 1998-11-12 | William Edward Bondinell | Protease inhibitors |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| DK0877019T3 (da) | 1997-05-09 | 2002-04-08 | Hoechst Ag | Substituerede diaminocarboxylsyrer |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| HUP0100520A3 (en) | 1998-01-23 | 2002-11-28 | Genentech Inc | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| DE19815547C1 (de) | 1998-04-07 | 1999-12-02 | Joachim Schmidt | Haftmittel für Zahnprothesen |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| CN1418210A (zh) | 2000-03-21 | 2003-05-14 | 宝洁公司 | 含有碳环侧链的n－取代金属蛋白酶抑制剂 |
| AU2001264595A1 (en) | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| WO2002074298A1 (fr) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de production d'il-6 |
| JP2004535390A (ja) | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| TW200305396A (en) | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
| KR101088922B1 (ko) | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| DE10251170A1 (de) | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| ES2298753T3 (es) | 2003-05-07 | 2008-05-16 | The University Court Of The University Of Aberdeen | Cetonas y cetonas reducidas como agentes terapeuticos para el tratamiento de enfermedades oseas. |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2005025554A2 (en) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Dipeptidyl peptidase iv inhibitor |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| WO2005060963A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| WO2005105712A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Sulfonamide derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| CA2584413A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
| BRPI0620756B1 (pt) | 2005-12-29 | 2021-06-01 | Tersera Therapeutics Llc | Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1) |
| US7560597B2 (en) | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| WO2010025235A1 (en) | 2008-08-29 | 2010-03-04 | Regents Of The University Of Michigan | Selective ligands for the dopamine 3 (d3) receptor and methods of using the same |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
-
2013
- 2013-06-26 GB GBGB1311361.8A patent/GB201311361D0/en not_active Ceased
-
2014
- 2014-06-24 PT PT147356422T patent/PT3013799T/pt unknown
- 2014-06-24 EA EA201592308A patent/EA028077B1/ru unknown
- 2014-06-24 JP JP2016522860A patent/JP6360555B2/ja active Active
- 2014-06-24 ES ES14735642.2T patent/ES2641758T3/es active Active
- 2014-06-24 KR KR1020167002015A patent/KR102151299B1/ko active IP Right Grant
- 2014-06-24 ME MEP-2017-208A patent/ME02834B/me unknown
- 2014-06-24 DK DK14735642.2T patent/DK3013799T3/en active
- 2014-06-24 HU HUE14735642A patent/HUE034983T2/en unknown
- 2014-06-24 EP EP14735642.2A patent/EP3013799B1/en active Active
- 2014-06-24 LT LTEP14735642.2T patent/LT3013799T/lt unknown
- 2014-06-24 CA CA2915075A patent/CA2915075C/en active Active
- 2014-06-24 NZ NZ715192A patent/NZ715192A/en unknown
- 2014-06-24 US US14/899,422 patent/US9624167B2/en active Active
- 2014-06-24 SG SG11201510646SA patent/SG11201510646SA/en unknown
- 2014-06-24 SI SI201430364T patent/SI3013799T1/sl unknown
- 2014-06-24 PL PL14735642T patent/PL3013799T3/pl unknown
- 2014-06-24 MX MX2015016914A patent/MX2015016914A/es active IP Right Grant
- 2014-06-24 AU AU2014300745A patent/AU2014300745B2/en active Active
- 2014-06-24 CN CN201480047140.2A patent/CN105492426B/zh active Active
- 2014-06-24 BR BR112015031527-5A patent/BR112015031527B1/pt active IP Right Grant
- 2014-06-24 RS RS20170876A patent/RS56256B1/sr unknown
- 2014-06-24 WO PCT/GB2014/051921 patent/WO2014207445A1/en active Application Filing
-
2015
- 2015-12-14 IL IL243103A patent/IL243103B/en active IP Right Grant
-
2016
- 2016-01-11 ZA ZA2016/00202A patent/ZA201600202B/en unknown
- 2016-05-23 HK HK16105875.1A patent/HK1218115A1/zh unknown
-
2017
- 2017-04-11 US US15/484,256 patent/US9796670B2/en active Active
- 2017-10-11 CY CY20171101060T patent/CY1119438T1/el unknown
- 2017-10-17 US US15/786,021 patent/US10029979B2/en active Active
- 2017-10-24 HR HRP20171611TT patent/HRP20171611T1/hr unknown
-
2018
- 2018-07-17 US US16/037,048 patent/US10233147B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171611T1 (hr) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena | |
| HRP20150858T1 (hr) | Inhibitori bromodomena i njihove uporabe | |
| JP2011510632A5 (hr) | ||
| PH12017500635B1 (en) | Aminopyridyloxypyrazole compounds | |
| PH12017501989A1 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| MY192641A (en) | Novel pyrimidine and pyridine compounds and their usage | |
| PH12015502563B1 (en) | Bipyrazole derivatives as jak inhibitors | |
| FI3882250T3 (fi) | TETRAHYDROPYRANYYLIAMINO-PYRROLOPYRIMIDINONI KÄYTETTÄVÄKSI HOIDETTAESSA BTK-VÄLITTEISiÄ HÄIRIÖITÄ | |
| UA114944C2 (uk) | Піридинільні і конденсовані піридинільні похідні триазолону | |
| EA201600373A1 (ru) | ПИРРОЛО[2,3-d]ПИРИМИДИНИЛ-, ПИРРОЛО[2,3-b]ПИРАЗИНИЛ- И ПИРРОЛО[2,3-d]ПИРИДИНИЛАКРИЛАМИДЫ | |
| NZ712479A (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| WO2013041251A3 (en) | Scintillation compound including a rare earth element and a process of forming the same | |
| HRP20211877T1 (hr) | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba | |
| JP2016529218A5 (hr) | ||
| JP2019502675A5 (hr) | ||
| JP2017507175A5 (hr) | ||
| JP2018500287A5 (hr) | ||
| RU2018113718A (ru) | Новые соединения | |
| JP2018516994A5 (hr) | ||
| JP2012502111A5 (hr) | ||
| JP2016539985A5 (hr) | ||
| JP2018509380A5 (hr) | ||
| RU2017107681A (ru) | Производные хиназолина | |
| NZ609585A (en) | Clay-bearing manufactured sands for hydratable cementitious compositions | |
| RU2016135192A (ru) | Дейтерированные соединения хиназолинона и содержащие их фармацевтические композиции |